Wall Street: GLP-1 competitors’ pain is Eli Lilly’s gain
Eli Lilly’s stock continued its wild ride Wednesday after lackluster data from Amgen’s potential GLP-1 competitor further demonstrated tirzepatide’s advantage.
On Wednesday, Lilly shares $LLY spiked nearly 5% before closing at $725.38, still a 3% increase for the day. Those gains were likely fueled by a less-than-positive investor response to Amgen’s GLP-1 program, reinforcing tirzepatide’s leading position.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
